Global Endobronchial Ultrasound Biopsy Market - 2021-2028
発行: DataM Intelligence
ページ情報: 英文 180 Pages
The global endobronchial ultrasound biopsy market size was valued at US$ XX million in 2020 and is estimated to reach US$ XX million by 2028,growing at a high CAGR of XX % during the forecast period (2021-2028).
Endobronchial ultrasound is a minimally invasive but highly effective procedure for diagnosing lung cancer, infections, and other diseases with enlarged lymph nodes in the chest.An EBUS uses a bronchoscope tool to do this, and no surgical cuts will be made in the chest for this procedure.
The factors driving the market growth are technological advancements in EBUS devices, consumer preference for minimally invasive surgeries, the rising prevalence of respiratory diseases such as tuberculosis, and the high number of people who have lung cancer are all contributing factors.
Over the last decades, technological advancements have enabled pulmonologists to perform endobronchial ultrasounds (EBUS). The multilayered structure of the tracheobronchial wall can be analyzed better with an EBUS mini-probe than with any other imaging modality. It can be used to biopsy peripheral lesions instead of fluoroscopic guided biopsy. For mediastinal lymph node staging of lung cancer, EBUS-transbronchial needle aspiration has proven useful.Other than EBUS RP, new techniques have emerged in the last decade to help guide and biopsy PPLs(peripheral pulmonary lesions)through the tracheobronchial tree during bronchoscopy. Virtual bronchoscopy (VB) and electromagnetic navigation bronchoscopy (ENB) can generate a virtual image for biopsy. ENB provides approach directions in real-time. When ENB or VB are used for biopsy, the diagnostic yield is comparable to EBUS RP guidance biopsy. However, the diagnostic yield increases significantly when two combined methods, such as EBUS RP + ENB or EBUS RP + VB. Another tool for improving diagnostic accuracy is ultrathin bronchoscopy. It has a 3.0 mm diameter and includes a working channel.
The other method which is expected to drive the market is the ROSE of EBUS-TBNA. It is a well-established tool for improving procedure yield. Rapid on-site evaluation in conjunction with TBNA reduces the cytopathology laboratory's workload by significantly reducing pulmonologists' total number of slides compared to samples without ROSE. Most importantly, ROSE results in better patient care. When ROSE is used, different clinical trials and large series have reported lower complication rates.
For example, on February 25, 2021, Rela Hospital in Chennai launched EBUS (Endobronchial Ultrasound) Bronchoscopy. It is one of the city's few that has this technology. The hospital carries out EBUS bronchoscopy procedures and FNA biopsy via EBUS by ROSE method.
Sedation complications include hypoxemia and hypotension, whereas bronchoscopy complications include bronchospasm, laryngospasm, nausea, vomiting, bleeding due to scope trauma, cardiac arrhythmias, and vasovagal syncope. Pneumothorax and bleeding are two complications associated with EBUS-TBNA.Furthermore, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a sophisticated technique that requires expertise and experience to implement effectively. Evidence-based procedures for training pulmonologists in the area of EBUS-TBNA are required; however, there are currently no such accepted or standard techniques for assessing EBUS technical skills and competencies, which would hamper the market's growth. And the high cost of these medical devices and a lack of proper reimbursement policies in emerging economies may potentially restrain the market.
Bronchoscopy is widely regarded as an aerosol-generating procedure (AGP). This, combined with the prioritization of preserving limited personal protective equipment (PPE) stock, resulted in unanimous agreement that non-urgent bronchoscopy be postponed until the coronavirus disease 2019 (COVID19) pandemic had passed.Bronchoscopy is used in patients with suspected or confirmed COVID-19 infection, according to current guidelines. Patients continue to present with symptoms and findings unrelated to COVID-19 infection throughout the pandemic but due to suspected lung cancer. Bronchoscopy remains a potentially harmful procedure in these patients. Because of the medical field's focus on treating COVID-19, funding for R&D activities related to endobronchial ultrasound biopsy has been reduced. It has been neglected, resulting in a negative impact on the endobronchial ultrasound biopsy market.
The higher prevalence of the SARS-CoV-2 virus in people with lung disorders, on the other hand, is associated with higher mortality and morbidity rates, which is expected to drive up market demand for endobronchial ultrasound biopsy devices.
Transbronchial needle aspiration (TBNA) is a technique for obtaining cellular material by passing a needle through the bronchial wall. It is used to obtain tissue from lesions of the lung or hilar/mediastinal system that are close to the endobronchial tree.TBNA allows for the minimally invasive diagnosis and staging of pulmonary, hilar, and mediastinal lesions (particularly lung cancer) and evaluating these areas for non-malignant pathology such as sarcoidosis. Despite these benefits, TBNA has previously been an underutilized technique, a trend that may change as trainees gain more experience with the procedure.The recent advancement of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) reignited interest and confidence in TBNA. Conventional transbronchial needle aspiration refers to TBNA without EBUS (C-TBNA).
For instance, the role of Boston Scientific company's eXcelon Transbronchial Aspiration Needle is designed to aspiration bronchial tree lesions in the carinal, paratracheal, and hilar regions where biopsy forceps cannot obtain a submucosal sample.Technological advances and widespread use of these needles in gastroenterology and pulmonology are expected to drive the market in the forecast period.
An increase in lung cancer and chronic respiratory disease, product launches and FDA approval in this region is expected to drive the market growth.
According to The American Cancer Society in the United States, in 2021, there will be approximately 235,760 new cases of lung cancer each year (119,100 in men and 116,660 in women). Lung cancer claimed the lives of approximately 131,880 people (69,410 in men and 62,470 in women). Lung cancer primarily affects the elderly. Most of the people diagnosed with lung cancer are 65 or older. Only a small number of people diagnosed are under 45. It is the leading cause of cancer death in both men and women, accounting for nearly 25% of all cancer deaths.Bronchoscopy with EBUS (endobronchial ultrasound) is a procedure used to diagnose various types of lung disorders, such as inflammation, infections, or cancer. And with the increasing incidence of lung cancer, the market is expected to grow in the forecast period.
On February 20, 2019, The US Food and Drug Administration (FDA) approved Intuitive Surgical Inc.'s Ion endoluminal system for minimally invasive biopsy in the peripheral lung.
The global endobronchial ultrasound biopsy market is moderately competitive with major key players' FDA approvals, company megers and product launches.
The key players in the global endobronchial ultrasound biopsy market are Medtronic plc, Olympus Corporation, Clinodevice, CONMED Corporation, Medi-Globe Corporation, Boston Scientific Corporation, Veran Medical Technologies, Simbionix USA Corporation, FUJIFILM Corporation and Cook Group Incorporated.
The global endobronchial ultrasound biopsy market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.